Prognostic biomarkers of eclampsia: A meta-analysis
Mugazov M.M. Omertayeva D.E. Vasiliyev D.V. Vasiliyeva N.N. Khoroshavtseva L.A. Romashkova A.K.
1 April 2025Kaz Med Print LLP
Reproductive Medicine (Central Asia)
2025#2025Issue 134 - 40 pp.
Relevance: Eclampsia is a life-threatening pregnancy complication characterized by seizures and loss of consciousness on the background of preeclampsia. The WHO estimates that 10–15% of maternal mortality is associated with hypertensive disorders, including eclampsia. The study aimed to comprehensively analyze key biomarkers for predicting eclampsia based on high-quality studies from the last 10 years. Materials and Methods: he study included 40 research papers from the PubMed, Scopus, and Cochrane Library databases focusing on biomarkers such as sFlt-1/PlGF, cell-free DNA (cfDNA), and genetic markers of inflammation. Data analysis was performed using the PRISMA method, with odds ratios (OR) and 95% confidence intervals (CI) calculations. Results: The sFlt-1/PlGF ratio was the most accurate predictor of eclampsia (OR = 7.5; 95% CI: 5.6-9.9; p < 0.001). Levels of cfDNA (OR = 6.3; 95% CI: 4.7-8.4; p < 0.001) and polymorphisms of the IL-10 and TNF-α genes (OR = 3.9; 95% CI: 2.8-5.4; p < 0.001) were also significant. Conclusion: The combined use of sFlt-1/PlGF, cfDNA, and genetic tests enhances the accuracy of eclampsia prediction and presents significant clinical potential.
biomarker , eclampsia , prediction , preeclampsia , pregnancy
Text of the article Перейти на текст статьи
Emergency Care, Anesthesiology and Resuscitation Department, Karaganda Medical University, Karaganda, Kazakhstan
Obstetrics, Gynecology and Perinatology Department, Karaganda, Kazakhstan
Emergency Care
Obstetrics
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026